Ang-(1–7) is a heptapeptide discovered in 1988 in the brainstem by Santos et al. (1988). The first characterization of the peptide described it as an Ang I´s metabolite by ACE enzymatic action. However, after ACE inhibition, Ang-(1–7) was still detectable, suggesting that other enzymes could generate this peptide (Santos et al., 1988). Some years later, ACE2 was identified as an ACE homolog, that was able to hydrolyze Ang II to Ang-(1–7) (Tipnis et al., 2000) and Ang I to Ang-(1–9) (Donoghue et al., 2000). Unlike ACE, ACE2 is tissue-specific, firstly described as expressed only in heart, kidney, and testis (Donoghue et al., 2000), to then be shown to express in many other tissues, as enterocytes, reproductive cells, eyes, etc. (Hikmet et al., 2020). Subsequently, Ang I can also be converted into Ang-(1–7), via either cleavage by ACE 2, to form Ang-(1–9) which is then hydrolyzed by ACE transforming it into Ang-(1–7), or by a direct conversion by the action of prolyl endopeptidase, neutral endopeptidase or thimet oligopeptidase (Welches et al., 1993) (Figure 1). Although it has been proved that ACE2 has higher catalytic efficiency on Ang II to form Ang-(1–7), its formation at least in failing human heart, has been reported also by NEP suggesting that its pathway generation is dependent of physiological conditions (Vickers et al., 2002; Zisman et al., 2003; Rice et al., 2004). Ang-(1–7) acts through engaging the orphan Mas proto-oncogene (Santos et al., 2003). However, there is evidence that shows Ang-(1–7) can also bind to AT₂R although with less specificity (Bosnyak et al., 2011).

The first described actions for Ang-(1–7) were in the cardiovascular system, where it inhibited Ang II-induced vasoconstriction (Roks et al., 1999; Jiang et al., 2014). Afterward, several studies have shown anti-inflammatory and antifibrotic effects in different pathological conditions (Figures 2, 3). There is evidence that Ang-(1–7) treatment alleviates induced inflammation by cecal ligation and puncture in murine models (Passaglia et al., 2023). Ang-(1–7) reduced expression of proinflammatory cytokines TNF-α and IL-6 while augmenting anti-inflammatory cytokines IL-4 and 10 and promoting M2 macrophage polarization. These effects were accompanied by a decrease in NF-kB phosphorylation, suggesting that Ang-(1–7) inhibits inflammation through this pathway (De Carvalho Santuchi et al., 2019; Pan et al., 2021). In another study using a E. coli-induced peritonitis, administration of Ang-(1–7) promoted the recruitment of M2 macrophages, increasing its phagocytic capacity, and increased the production of IL-10, MCP-1. These effects were inhibited in the absence of the Mas receptor, suggesting that Ang-(1–7) could contribute to the resolution of inflammation through the Mas receptor (Zaidan et al., 2022).

Furthermore, the role of Ang-(1–7) during sepsis has been evaluated. The infusion of this peptide prevented septic shock in different animal models, limiting the amount of IL-6 cytokine, nitric oxide (NO) production and decreasing renal, lung and liver damage, along with IκB kinase pathway inhibition, suggesting that Ang-(1–7) ameliorate sepsis-induced organ injury likely through the inhibition of an inflammatory response (Tsai et al., 2021; Garcia et al., 2023). In the septic process, an increase in Ang II levels has been shown and is associated with renal and myocardial injury with an increase in cytokine levels (Zhu et al., 2021; Chen X. S. et al., 2023). It has been found that administration of Ang-(1–7) decreases inflammatory cells infiltration as well as the production of IL-6, IL-1β, and TNF-α in myocardial and renal tissue of septic mice. Additionally, a higher survival percentage and a decrease of Ang II levels were observed in mice that were administered with Ang-(1–7) compared to untreated mice suggesting that treatment with this peptide could attenuate the organic damage caused by sepsis (Xu et al., 2021; Zhu et al., 2021; Chen X. S. et al., 2023).

During the recent coronavirus pandemic, researchers found that there was a RAS dysregulation and ACE2 dysfunction due to SARS-COV-2 binding to ACE2 receptor in host cells, driving to acute respiratory distress syndrome. COVID-19 patients exhibit reduced Ang-(1–7) levels compared to control individuals and this phenomenon was associated with the severe form of the disease (Carpenter et al., 2022). Therefore, the peptide was also suggested as a therapy in COVID-19 ill patients confirmed with high viral load and co-morbidities such as hypertension, diabetes, heart diseases and asthma. Plasma enriched with Ang-(1–7) was transfused in combination with favipiravir treatment and, in almost all cases, the peptide transfusion improved oxygen saturation and clinical status (Onal et al., 2022). It has been shown that SARS-COV-2 infect bronchoalveolar stem cells (BACS). BACS are a lung resident stem cell population that differentiate into many types of cells, contributing to the maintenance of bronchoalveolar duct. In response to injury, BACS ratio increases and promotes tissue repair, which is impaired when viral infection. In mice, Ang-(1–7) administration increased the percentage of BACS and decreased protein expression involved in programmed cell death and inflammation process, suggesting that Ang-(1–7) peptide treatment could have a protective function in lung injury by SARS-CoV-2 (Ciechanowicz et al., 2022). In addition, Ang-(1–7)´s in vitro treatment of human pulmonary alveolar epithelial cells stimulates with SARS-COV-2 spike protein reduced production of IL-6, IL-8 and suppressed ERK1/2 and AP-1 phosphorylation, suggesting that Ang (1–7) could block SARS-COV-2-exacerbating proinflammatory response (Shen et al., 2023).

On the other hand, there is experimental evidence indicating Ang-(1–7)/Mas pathway may contribute to the attenuation of airway pathological conditions. Asthma is a chronic allergic airway disease and is characterized by airway hyperresponsiveness and pulmonary remodeling in which inflammatory response play an important role with a predominance of eosinophils, increased IL-4, IL-5, IL-13, TNF-α cytokines, and chemokines such as MCP-1 and CCL5 (Magalhães et al., 2016). Ovalbumin challenge in mice is used as an experimental asthma model, since it replicates the pathophysiological features in patients (Magalhães et al., 2015). In previous studies using this model, Ang-(1–7) treatment statistically diminished the release levels of IL-4, IL-5 cytokines and MCP-1 and CCL-5 chemokines into serum, as well as granulocyte-macrophage colony-stimulating factor. Consequently, reducing inflammatory cell infiltrate, alveolar wall thickening and airway collagen I and mucus deposition (Magalhães et al., 2015). In addition, Ang-(1–7) administration upregulated Mas expression on bronchial cells and decrease epidermal growth factor receptor (EGFR), Src kinase and ERK1/2 phosphorylation in lung tissue (El-Hashim et al., 2019). Nonetheless, it has been demonstrated that Mas deficiency aggravates chronic allergic pulmonary inflammation, suggesting that Mas is an important receptor to trigger anti-inflammatory response and could be doing it through mediation of EGFR/Src/ERK1/2 pathway on lung tissue (Magalhães et al., 2016). Additionally, ATG5 is a key protein involved in the formation of autophagosomes overexpressed in lung tissue of asthma patients. Interestingly, Ang-(1–7) elicited decreased levels of ATG5 on human bronchial epithelial and smooth muscle cells. This ATG5 deficiency suppressed inflammation and airway fibrosis, similarly to what it was observed in ovalbumin-challenged mice with Ang-(1–7) administration, suggesting another mechanism for Ang-(1–7) as an asthma treatment (Xu et al., 2023).

As already mentioned, the end result of inflammation is fibrosis. In models of acute lung injury mimicking acute respiratory distress syndrome in humans, the action of Ang-(1–7) have been examined. In this syndrome, there is a disruption of epithelial and endothelial barriers in the lung leading to severe immune reactions, hypoxic respiratory failure, pulmonary edema, and fibrosis (Chen et al., 2013). In acute lung injury, the characteristic increase in the expression of collagen I and III, TGF-β, IL-6, and Smad2/3 in the lung, is reduced after Ang-(1–7) therapy, leading to a significant improvement in oxygenation and reduction of white blood cells counts mainly in neutrophil percentage (Chen et al., 2013; Zambelli et al., 2015; Wang et al., 2022). In addition, Ang-(1–7) infusion, starting immediately after lung injury, has also been shown to prevent pulmonary vascular resistance, diminish aortic pressure, and increase ACE2 activity in lung tissue (Supé et al., 2016). Ang II-induced pulmonary fibrosis in rats triggers a cascade of proinflammatory factors and adhesion molecules that allows infiltrate cells recruitment in the lung, mediated by phosphorylation of ERK1/2/NF-κB pathway. Interestingly, Ang-(1–7) treatment in Ang II-treated animals inhibited ERK1/2/NF-κB axis, proinflammatory cascade and ameliorated lung fibrosis, effects that were reverse by Mas antagonists. By contrast, in Ang-(1–7) alone group, exhibited lung inflammation and deposition of collagen I compared to the untreated group (Meng et al., 2014). Together these data showed, at least under pathological conditions, Ang-(1–7) can protect against fibrosis development down-regulating pathways such as ERK1/2/NF-κB, which makes it a therapeutic target in fibrotic conditions (Figure 3).

Ang-(1–7) has also been studied in fibrotic renal diseases. Renal diseases are characterized by interstitial cell infiltration, NF-κB activation, increased apoptosis, oxidative stress, and fibrosis, even when patients with renal failure present complications in other organs such as heart. In previous studies in renal injury models, long-term treatment with Ang-(1–7) decreased the production of pro-inflammatory cytokines, macrophage infiltrate, caspases cleavage and blood pressure, as well as attenuating Ang II levels meliorating oxidative stress and renal fibrosis (Lu et al., 2017; Zaman and Banday, 2022). Moreover, treatment was able to increase the activity of enzymes involved in collagen degradation, and improved heart function accompanied by a reduction in cardiac fibrosis (Li et al., 2009). Interestingly, in renal failure models, Mas receptor deficiency inhibited NF-κB phosphorylation leading to reduction in MCP-1 and IL-6 cytokines and thus attenuating the fibrotic condition. Similar results were observed when wildtype experimental models were infused with short-term Ang-(1–7) treatment, suggesting that in some conditions, lack of signaling by Mas could prevent renal inflammation (Esteban et al., 2009).

One of the most studied actions of Ang-(1–7) is in cardiac remodeling. Many authors have confirmed that Ang-(1–7) has some effect in at least one of the components of cardiac remodeling. Grobe et al. demonstrated reduced myocyte hypertrophy, interstitial fibrosis and TGF-β levels in response to Ang-(1–7) in an Ang II-induced rat model of hypertension and cardiac remodeling (Grobe et al., 2007). Studies with transgenic mice overexpressing Ang-(1–7) in the heart have shown that in the presence of Ang II, hypertrophy and fibrosis of the left ventricle is reduced, as well as expression of TGF-β1 (Mercure et al., 2008). In cardiac fibrosis, exposure of Ang II-stimulated cardiac fibroblasts to Ang-(1–7) inhibited collagen synthesis and expression of endothelin-1 and leukaemia inhibitory factor (Iwata et al., 2005). It has also been described that Ang-(1–7) normalizes the decreased levels of MMP in Ang II-stimulated cardiac fibroblasts and myocytes (Pan et al., 2008). In addition, Grobe et al. (2006) showed that Ang1-(1–7) was able to prevent interstitial fibrosis by decreasing collagen deposition in the deoxycorticosterone acetate (DOCA) salt hypertensive rat model (Grobe et al., 2006). In nephrectomised mice Ang-(1–7) prevented left ventricular remodeling and diminished interstitial fibrosis by reducing the levels of TGF-β and increasing MMP2 and 9 (Li et al., 2009). Ang-(1–7) also decreased the expression levels of inflammatory cytokines and suppressed oxidative damage (Li et al., 2009) (Figure 3). It has been demonstrated that oxidative stress, vasoactive peptides, and inflammation can induce DNA damage, mitochondrial dysfunction, and protein misfolding leading to senescence and cell death (Erusalimsky, 2009). Endothelial senescence has been associated with cardiovascular diseases and atherosclerotic lesions (Mogi, 2020). Regarding Ang-(1–7), Romero et al. (2019), studied the heptapeptide role in endothelial cells senescence-induced by RAS or non-RAS mechanism. They found that Ang-(1–7) antagonized the cell senescence triggered by Ang II and IL-1β, which were blunted by A779 (Mas antagonist). The pro-inflammatory phenotype also was reduced after peptide treatment, which included a reduction in adhesines such as ICAM-1, VCAM, and IL-6 secretion. Additionally, the nuclear factor-erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) levels were augmented after Ang-(1–7) and inhibited when these pathways were blocked. These data suggest that Ang-(1–7) could prevent Ang II and IL-1β senescencent-induced effects by reducing oxidative stress by MasR/Nrf2/HO-1 axis (Romero et al., 2019). As mentioned above, oxidative stress and cytokine production can trigger cell senescence. Several reports on ROS dysregulation are related to the development of fibrosis diseases (Li et al., 2020). Due to that in fibrosis, there is low-grade chronic inflammation, which triggers excessive ROS production and may promote TGF-β synthesis leading to fibroblast activation with consequent ECM deposit accumulation. Hence, it could be interesting to study the pathways related to aging and fibrosis development.

Ang-(3–8), also known as Ang IV, is a hexapeptide generated through the cleavage of Ang III by aminopeptidase N. This peptide of only six amino acids long has been shown to have vasodilatory and inflammatory actions in different organs. The role of Ang-(3–8) in inflammation was described for the first time in 2005. The capacity of this peptide to activate the transcription factor NF-κB and positively regulate inflammation was demonstrated in vascular smooth muscle cells through the AT₄R receptor (Esteban et al., 2005). On the contrary, studies have emerged establishing Ang-(3–8) having anti-inflammatory effects. In human endothelial cells, the capacity of Ang IV to mediate the expression of Macrophage Migration Inhibitor, a proinflammatory cytokine associated with the production of TNF-α, IL-1β and IL-6, was observed (Zhong et al., 2008). In murine macrophages, Nikolaou et al. (2014), evaluated the effects of Ang IV on the NF-κB pathway, where a lack of expression of proinflammatory genes such as ICAM-1 and TNF-α was observed, which could indicate differential effects of this peptide depending on cell lineage (Nikolaou et al., 2014). In a murine model of abdominal aortic aneurysm, treatment with Ang IV markedly reduced the infiltration of macrophages and proinflammatory cytokines (Kong et al., 2015). Furthermore, in cardiac ischemia-reperfusion (I/R) injury, Ang-(3–8) infusion managed to suppress the expression of VCAM-1, TNFα, MMP-9, and NF-κB proteins (Figure 3) (Park et al., 2016). Similar results were described in rats with cerebral hypoperfusion, where in addition to observing anti-inflammatory effects, it was discovered for the first time that this effect was induced in a dose-dependent manner (Wang et al., 2018). More recently, in mice, it was demonstrated how Ang IV was able to protect against acute myocardial infarction by inhibiting inflammation (Bai et al., 2021).

In a fibrotic context, little is still known in relation to Ang IV. However, some studies have demonstrated an interaction between this peptide and fibrotic pathologies. In a study performed in kidney cells, the capacity of Ang IV to induce the expression of plasminogen activator inhibitor-1 mRNA, a protein involved in fibrosis inhibition and progression of fibrotic events, was demonstrated (Gesualdo et al., 1999). Ang-(3–8) also induced interstitial fibrosis and cardiac deterioration in adult mouse hearts when bound to the AT₁R receptor (Ainscough et al., 2009). Conversely, Ang IV dose-dependently downregulated Fox01-mediated fibrosis when bound to the AT4 receptor in a mouse model of diabetic cardiomyopathy (Zhang M. et al., 2021) (Figure 3).

Ang-(1–9) is a nine amino acid peptide that results from the metabolism of Ang I by ACE2 cleavage of the terminal amino acid (Donoghue et al., 2000). Although ACE2 is the main enzyme to form Ang-(1–9), carboxypeptidase A and cathepsin A can also produce this peptide (Jackman et al., 2002; Garabelli et al., 2008). These reports also show that formation of Ang-(1–9) from Ang I is the main pathway in cardiomyocytes (Kokkonen, et al., 1997; Garabelli et al., 2008). As already mentioned, once Ang-(1–9) is formed ACE cleaves the two last amino acids (phenylalanine and histidine) generating the active peptide Ang-(1–7). Ang I is the precursor to Ang-(1–9) through ACE2 (Figure 1). Although little is known about it, Ang-(1–9) has gained relevance as a counterregulatory active peptide. Ang-(1–9) binds mainly to the AT₂R (Flores-Muñoz et al., 2011), exerting biological effects in organs such as kidney, lung and mainly heart.

Few studies have described Ang-(1–9) in an inflammatory context (Figure 2). In rats with diabetic heart disease, subcutaneous administration of this peptide normalized the levels of several proinflammatory cytokines, including TNF-α and IL-1β through the AT₂R (Zheng et al., 2015). In DOCA-salt hypertensive rats, infusion of Ang-(1–9) decrease monocyte infiltration in heart, aorta and kidney tissue, reducing inflammation in these rats (Gonzalez et al., 2018). Similar results were also observed in a rat model of pulmonary hypertension, where treatment with Ang-(1–9) reduced plasma TNF-α, MCP-1, IL-1β, and IL-6 (Cha, et al., 2018). Furthermore, in prostate cancer cells Ang-(1–9) negatively regulated the expression of NF-κB1 and NF-κB2, modulating these inflammatory pathways (Domińska et al., 2020)

Within the fibrotic context Ang-(1–9) was shown to be capable of reducing cardiac fibrosis through the AT₂R, by reducing the presence of type I collagen in spontaneously hypertensive rats (Flores-Munoz et al., 2012). Similarly in rats with Ang II-induced hypertension, this peptide was able to reduce the presence of collagen type I, in addition to reducing the expression of TGF-β (Ocaranza et al., 2014). These results were also observed in diabetic rats where collagen I and TGF-β mRNA expression was also decreased (Zheng et al., 2015). Adenoassociated delivery of Ang-(1–9) in mice infarcted hearts, reduced septal and perivascular fibrosis, as well as expression of MMP-12, described as promoter of fibrosis (Fattah et al., 2016). Furthermore, Fattah et al. (2016), described that Ang-(1–9) delivery, while reducing fibrosis, it also reduced acute rupture by stabilizing and thickening myocardial infarction scar, suggesting Ang-(1–9) remodeling modulation during scar evolution. Gonzalez et al. (2018), described Ang-(1–9) as having a protective role in hypertensive end-organ damage, by demonstrating reduction of collagen deposition and myofibroblast in heart, kidney and aorta when infused in DOCA-salt hypertensive rats (Gonzalez et al., 2018). Additionally, in rats with pulmonary hypertension the antifibrotic effects of Ang-(1–9) were replicated. Treatment with Ang-(1–9) in an monocrotaline induced pulmonary hypertensive model reduced pulmonary damage via the AT₂R (Cha et al., 2018) (Figure 3).

Alamandine is a recently discovered heptapeptide derived from Angiotensin A, very similar to Ang-(1–7), differing only by presenting alanine instead of aspartate in the N-terminal domain (Lautner et al., 2013). Due to this similarity, alamandine has been shown to have similar actions to Ang-(1–7). However, these actions have been associated with its interaction with a different receptor, the Mas-related G protein-coupled receptor, member D (MrgD) (Lautner et al., 2013) (Figure 2). Within the inflammatory context, in vitro experiment showed that alamandine was able to dose-dependently regulate the degranulation of MMP-9 and myeloperoxidase in mouse neutrophils, suggesting an anti-inflammatory role (Da Silva et al., 2017). Later, in a murine model of cardiac dysfunction associated with sepsis, this peptide was able to prevent myocardial inflammation, by preventing the activation of ERK, JNK and P38 (Li et al., 2018). Furthermore, in mice subjected to a transverse aortic constriction procedure, it was observed that alamandine was able to decrease the expression of proinflammatory genes MCP-1, TNF-α, IL-1β and contribute to resolution with an increased expression of MRC1 and FIZZ1 (Morais Silva, 2020). Similar results were observed in a myocardial ischemia-reperfusion injury model where alamandine reduced the levels of TNF-α, IL-1β, IL-6 and NO, and protected cardiomyocytes by inhibiting the activation of NF-κB (Song et al., 2019). Therapeutic administration of this peptide decreased the number of neutrophils and M1 macrophages in a model of LPS-induced inflammation (De Carvalho Santuchi et al., 2019). Recently, alamandine was able to reduce doxorubicin-induced cardiotoxicity in rats, by counteracting the elevation of proinflammatory cytokines (Hekmat et al., 2021). In the kidney, this peptide also demonstrated anti-inflammatory actions by alleviating kidney injury by inhibiting PI3K/AK and MAPK pathways (Hu et al., 2021). Furthermore, alamandine was shown to have a protective role in a stroke model by reducing the expression of proinflammatory cytokines (TNFα, IL-1β, IL-6) (Figure 2; 3) (Gonçalves et al., 2022). Such protective effects were also observed in a collagen induced arthritis model (Ding et al., 2022).

Alamandine has also been described as having antifibrotic effects in different pathologies. Oral treatment of alamandine to spontaneously hypertensive rats resulted in decrease of collagen I, III and fibronectin expression of (Lautner et al., 2013; Liu et al., 2017). Similarly, administration of alamandine regulated vascular remodeling of ascending aorta by diminishing aortic fibrosis, collagen deposition, MMP activity and TGF-β expression in a murine model of transverse aortic contrition, as well as several important pro inflammatory genes (MCP-1, TNF-α, IL1-β) (De Souza-Neto et al., 2019). These effects are mediated through the MrgD receptor (Yang et al., 2020). In a subsequent study, when analyzing cardiac remodeling, alamandine administration reduced collagen deposition, MMP-2 and TGF-β expression in the left ventricle, induced by aortic constriction. Additionally, alamandine prevented ERK1/2 and AMPKα phosphorylation, suggesting important effects of alamandine in cardiac remodeling regulation (Morais Silva, 2020). Furthermore, Wang et al. (2023), suggested that alamandine antifibrotic effects on TGF-β activated fibroblast could be mediated by decreasing glycolysis through Parkin/CSF mitophagy (Wang et al., 2023). NF-κB and JNK pathways have been linked to alamandine actions. In a rat model of cardiac ischemia-reperfusion injury, the administration of this peptide reduced the presence of fibrotic markers, increasing the phosphorylation levels of ERK and JNK, while NF-κB decreased (Song et al., 2019). Another mechanism associated with the effects of alamandine was observed in liver and lung, where the peptide attenuated the presence of fibrosis by attenuating autophagy activated by ROS-dependent reactive oxygen species (Huang et al., 2020; Gong et al., 2022; Zhao et al., 2022). (Figure 3).

Currently, as part of the counter-regulatory RAS there are several other angiotensin peptides, but their role in inflammation or fibrosis has not been yet described. Within these, Ang III is a heptapeptide produced by Ang II cleaved in the Asp N-terminal residue, mediated by aminopeptidase A, and has been demonstrated to have high affinity to AT₁R but shows selectivity to AT₂R (Bosnyak et al., 2011). Ang III can induce NF-κB phosphorylation in mesangial cells and increase MAPK phosphorylation on VSMC, inducing proliferation. These effects are mainly mediated through the AT₂R (Lorenzo et al., 2002; Alanazi and Clark, 2020). In addition, low concentrations of Ang III perfusion have been demonstrated to stimulate stretch-induced atrial natriuretic peptide (ANP) secretion. ANP secretion was abolished when the AT₂R was blocked but not AT₁R or Mas. Interestingly, such an effect was also blocked by pretreatment with PI3K, Akt or PKG inhibitor, showing that ANP secretion may be stimulated by PI3K–Akt–PKG signaling pathway (Park et al., 2013). Moreover, intrarenal treatment with Ang III augmented urine sodium excretion in rats and increased AT₂R expression, effect that was abolished by an AT₂R antagonist (Padia et al., 2009). In addition, Ang III treatment produced a significant reduction of diastolic blood pressure in spontaneously hypertensive rats (Matsufuji et al., 1995). However, in another study, Ang III infusion failed to increase urine sodium excretion rate and AT₂R upregulation suggesting that the natriuretic effect is mediated by AT₂R signaling (Padia et al., 2009; Kemp et al., 2019). These data together suggest that Ang III could have an important pathologic role in renal diseases; however, further studies are needed to understand its clinical implications.

On the other hand, Ang-(3–7) is formed by cleavage of the Pro-Phe amino acid residue from Ang IV by carboxypeptidase P (Wright et al., 2012). Early studies that evaluated Ang-(3–7) showed its pressor effect in rats (Ferreira A. J. et al., 2007). Subsequently, the role has been studied in vitro in prostate epithelial cells, observing that Ang-(3–7) incubation led to upregulation of MIK67, NF-κB gene expression, and mobility was increased (Domińska et al., 2020). Additionally, Ang-(3–7) administration reduced heart weight and cardiac hypertrophy gene markers ANP, BNP, and β-MHC. Furthermore, the peptide treatment inhibited collagen I, collagen III, and fibronectin expression in hearts’ mice and cardiac fibroblast cells. These results indicated that Ang-(3–7) could attenuate cardiac hypertrophy and prevent fibrosis development in experimental cardiac remodeling model (Zhang Y. et al., 2021).

Ang-(3–4) is one of the shorter peptides in the counter-regulatory RAS that has been shown to have some effects. It is produced from Ang III metabolism in plasma (Matsufuji et al., 1995) or by Ang-(1–7) cleavage in the kidney (Axelband et al., 2009). The first studies showing some effect of this peptide demonstrated a role as an antihypertensive, antiproliferative, and vasodilatory agent (Matsufuji et al., 1995; Matsui et al., 2005; Dias et al., 2017). In hypertensive models, it has been found that oral administration of Ang-(3–4) produced a reduction in systolic blood pressure, as well as urinary sodium excretion increased and AT₁R downregulated in the renal proximal tubule of young rats (Saito et al., 1994; Luzes and Crisóstomo, 2021). Interestingly, the dipeptide depressor effect was not significant in aged mice (Matsui et al., 2003). In addition, in vitro studies show that Ang-(3–4) can also inhibit Ang II induced-human VSMC proliferation through intracellular Ca²⁺ suppression (Matsui et al., 2005). In a subsequent study, it was demonstrated ACE inhibition by dipeptide’s stimulus led to a reduction of Ang I-produced contraction of the aortic rings in rats (Vercruysse et al., 2008). Additionally, Ang-(3–4) effects are also investigated in overweight and undernutrition. In an overweight rat model, it was found that Ang-(3–4) treatment reduced blood pressure and hepatorenal index, suggesting that the peptide could prevent lesion formation induced by lipid deposits (Crisóstomo et al., 2022). Moreover, it has been found that in aging overweight and undernutrition juvenile rats, ACE2 levels decrease. Interestingly, after Ang-(3–4) administration, ACE2 levels are increased in overweight rats but not in rats with undernutrition conditions (Luzes and Muzi-Filho, 2021). In contrast, in a recent study, Pereira-Acácio et al. showed that a multi-deficient diet led to high blood pressure, and it could be associated with the development of hypertension (Pereira-Acácio et al., 2022). In this sense, they demonstrated that Ang-(3–4) treatment is capable of normalizing systolic blood pressure (Pereira-Acácio et al., 2022).

Finally, another recently studied peptide is Ang-(1–5). This pentapeptide is derived from Ang-(1–7) in vitro metabolism by the ACE enzyme, which hydrolyzes its Ile- His amino acid residues (Chappell et al., 1998). The most researched effects of pentapeptide are focused on the cardiovascular system. Roks et al. (1999), demonstrated that in vitro stimuli with Ang-(1–5) inhibited ACE activity from human plasma but is not capable of affecting arterial contractions (Roks et al., 1999). In addition, in isolated beating atria Ang-(1–5) stimulation induced augmented ANP secretion that was attenuated after inhibition of Mas, PI3K, Akt, and NOS, suggesting these pathways could be involved in ANP secretion stimulated by pentapeptide (Yu et al., 2016). Subsequently, the effect of Ang-(1–5) in Sprague-Dawley rats with I/R injury was evaluated. In this study, rats’ hearts were infused with low doses of Ang-(1–5) for 10 min prior to ischemic induction, further, they used AT₁R, AT₂R, and Mas antagonists. The Ang-(1–5) infusion ameliorated I/R-induced changes in left ventricular end-diastolic and developed pressure, cardiac infarct size and ANP secretion. These effects were abolished by the treatment with Mas antagonist, but not by AT₁R or AT₂R blockers. Moreover, the pentapeptide treatment also reduced pro-apoptotic proteins such as Bax, Caspase-3, and 9. However, anti-apoptotic proteins such as Bcl-2, and antioxidant enzymes such as Mn-superoxide dismutase, catalase, and HO-1 were increased. These effects were blocked when Mas was inhibited (Park, et al., 2021). Myocardial ischemic/hypoxia models are characterized by a gradual decrease in ANP secretion and changes in the profile of antioxidant enzymes and ROS production that lead to an increase in cell death (Park et al., 2021). Hence, this data together suggests that Ang-(1–5) treatment could attenuate myocardial damage in this pathology. Despite the recent evidence about the effects of these peptides, most reports are focused on their anti-hypertensive role. However, taken together all the available data, it could suggest that the upregulation of antioxidant pathways will lead to a reduction in ROS production with a consequent decrease in tissue damage to avoid chronic inflammation and fibrosis development.

Compound 21 (C21) is the first non-peptide agonist of the AT₂R. This agonist was synthesized in 2004 by Yiqian Wan, and through a binding assay they demonstrated the selective affinity of C21 for AT₂R. Additionally and most importantly, this new C21 had vasopressor effects in spontaneously hypertensive rats (Wan et al., 2004). The synthesis of this compound has facilitated the study of the specific effects of AT₂R. Antihypertensive, proangiogenic, antifibrotic and anti-inflammatory effects in different organs have been attributed to the interaction of C21 and AT₂R.

The anti-inflammatory actions of C21 with the AT₂R interaction have been studied in different pathologies. In a model of acute myocardial infarction in Wistar rats, the intraperitoneal administration of C21 was able to stimulate AT₂R, observing improvement in cardiac function and reduction of the scar in the post-infarction heart (Kaschina et al., 2008). In addition to these results, a null expression of p38 MAPK and p44/42 MAPK was observed. These MAPKs are traditionally involved in processes such as proliferative, apoptotic, and inflammatory. However, there is also evidence of opposite effects to those mentioned above. This association was demonstrated with evidence of anti-inflammatory actions, where C21 significantly suppressed the expression of cytokines (MCP-1, IL-1, IL-2, IL-6), so C21 contributed to the preservation of normal physiology after of myocardial infarction (Kaschina et al., 2008). Sampson et al., studied the involvement of C21 in TNF-α-induced inflammation in HUVEC, monocyte activation and in aortas of C57BL/6 mice. In vitro experiments indicated that C21 reduced TNF-α-induced expression of ICAM-1, CCL2, and IL-6 genes and proteins. In addition to reducing increased monocyte adhesion by 40% and reduced NFkB-p65 translocation from cytoplasm to the nucleus. These results were extrapolated to in vivo experiments, where treatment with C21 showed similar results (Sampson et al., 2016).

In renal pathological conditions, C21 counteracts most of the effects of the AT₁R. Matavelli et al. (2011), evaluated early renal inflammation in renovascular hypertension. In Sprague-Dawley rats treated with C21 for 4 days, a reversal of the early inflammatory stage was observed, with reduction of the proinflammatory markers TNF-α, IL-6 and TGF-β1 in kidney tissue (Matavelli, et al., 2011). Another study in 2015 evaluated the involvement of C21 in a model of early diabetes in rats, where one of its main objectives was to study the effects of this compound on kidney inflammation. In this case, in addition to seeing a marked reduction in IL-6, C21 also reduced TNF-α and markers of oxidative stress (Matavelli et al., 2015). Years later, Jabber et al. (2023), demonstrated in a murine model of sepsis-induced renal inflammation that the modulation of C21-induced inflammation was mediated by the modulation of the PI3K/AKT signaling pathways (Jabber, et al., 2023).

In the lung, C21, as in the heart and kidney, proved to have anti-inflammatory potential. In experiments carried out in mice with pulmonary inflammation induced by bleomycin, the contribution of C21 as a pulmonary anti-inflammatory was confirmed for the first time, observing a reduction in cellular infiltrate in bronchoalveolar fluid (Du et al., 2009). In subsequent studies, carried out by Menk et al. (2018), it was demonstrated that, in this organ, C21 could reduce not only the cellular infiltrate, but also the expression of TNF-α and IL-6 (Menk et al., 2018). Similar results were observed in Chronic obstructive pulmonary disease (COPD) induced by cigarette smoke, showing a reduction in proinflammatory cytokines and, also, the inhibition of components of the NF-κB signaling pathway in alveolar macrophages (Mei et al., 2022). Currently, with the emergence of the COVID-19 pandemic, the study of acute respiratory distress syndrome (ARDS) has gained relevance. In this sense, Chen et al. (2024), studied the relationship of C21 in ARDS, where favorably, this compound was able to resolve the inflammatory stage, with a marked reduction of CCL-2, IL-6 through NF-κB (Chen et al., 2024).

C21 has been shown to have antifibrotic actions in various cardiac pathologies. In 2012, Rehman et al. (2012), studied the involvement of C21 in the development of hypertension and vascular damage in stroke-prone spontaneously hypertensive rats. In these rats administered with C21 for 6 weeks, a decrease in fibrotic and hypertensive events was observed, associated with the reduction of the stiffness of the mesenteric artery, the decrease in myocardial interstitial collagen type I/III and aortic oxidative stress, infiltrate of inflammatory cells and fibronectin (Rehman et al., 2012). Subsequently, in rats with myocardial infarction, in addition to observing the ability of C21 to improve arterial stiffness and reduce collagen, a decrease in the extracellular matrix metalloproteases MMP2 and MMP9 and transforming growth factor B was observed (Lauer et al., 2013). Similarly, in another study of cardiac hypertrophy induced by high salt intake, C21 was able to replicate previous results (Dopona et al., 2019). In rats with Ang II-dependent hypertension, a sustained reduction in myocardial perivascular fibrosis was observed after 1 week of intraperitoneal administration of C21 (Castoldi et al., 2016).

In in vivo and in vitro experiments carried out in ydiabetic rats and mesangial cells, Koulis et al. (2015), demonstrated that the activation of AT₂R by C21 reduced the gene and protein expression of TGF-β1, CTGF, smooth muscle alpha actin and MMP-2 at the renal level. Furthermore, the effect of C21 on the extracellular matrix induced a reduction in type I and IV collagen (predominant collagen isotypes in renal fibrosis) (Koulis et al., 2015). In rats with cyclosporine-induced nephropathy, C21 reduced these same fibrotic markers, in addition to reducing glomerular and tubulo-interstitial fibrosis and macrophage infiltrate (Castoldi et al., 2016).

The presence of fibrosis in the lung can lead to decreased lung capacity, respiratory failure, and other complications such as heart problems. C21 has also been studied to treat fibrotic lung pathologies, with promising results. In a model of pulmonaryb hypertension in rats, induced by monocrotalin, the intraperitoneal administration of C21 decreased the presence of interstitial and perivascular collagen I, in addition to reducing the gene expression of profibrotic cytokines (TNF-α and IL-1β) (Bruce et al., 2015). Similarly, in a bleomycin-induced lung injury model in rats, administration of C21 at the same concentration reduced lung collagen accumulation, attenuated gene expression of fibrotic markers (Col 1, Col 3, Ctgf, Mmp12, Timp1, IL-13) (Rathinasabapathy et al., 2018). Recently, in a model of pulmonary hypertension induced by hypoxia in rats, C21 was administered intraperitoneally at two different doses. It was shown that this compound was able to reduce the presence of collagen fibers significantly at the dose of 20 mg/kg but not with the dose of 2 mg/kg (Tornling et al., 2023).

The compound AVE 0991 (AVE) was first described in 2002 by Wiemer et al. (2002). In this study they demonstrated that AVE 0991 mimicked the effects of Ang-(1–7) on endothelium, reducing the) release of nitric oxide, maintaining endothelial function, and reducing vascular injury (Wiemer et al., 2002), through the G protein-coupled receptor MAS (Pinheiro et al., 2004).

In heart diseases, AVE has been shown to induce beneficial effects for the resolution of pathologies. Zhou et al. (2019), in a murine model of transverse aortic constriction, tested the effects of AVE in combination with intraperitoneal captopril. Coadministration of these compounds completely prevented macrophage infiltration in the aortic adventitia. However, there was an accumulation of cells still present (Zhou et al., 2019). In another study of Ang II-induced hypertension in rats, AVE treatment in combination with alamandine reduced inflammatory stress related to the increase in MCP-1 (Tanrıverdi et al., 2023).

In an atherosclerosis model in knockout mice, AVE administered as treatment for 4 months, reduced the infiltration of proinflammatory cells MCP-1, IL-6, IL-12 and SAA (Jawien et al., 2012). Skiba et al. (2017), demonstrator that in this model, AVE 0991, inhibited inflammation in perivascular adipose tissue by reducing the expression of cytokines IL-1β, TNF-α, MCP-1 and CXCL10, and the differentiation of M2 macrophages to the M1 phenotype (Skiba et al., 2017).

This non-peptide agonist has also an anti-inflammatory effect in pulmonary pathologies. Rodrigues-Machado et al. (2013), evaluated the effects of AVE in a model of chronic asthma induced with ovalbumin in BALB/c mice. After administration of AVE for 28 days, this treatment was able to prevent the development of pulmonary and airway vascular remodeling, in addition to reducing the inflammatory response with a marked reduction in cytokine release (IL-5) in bronchoalveolar fluid and lung homogenates (Rodrigues-Machado et al., 2013). Subsequently, in a similar model it was observed that the anti-inflammatory effect (reduction of macrophages, MCP-1, MAPK) occurred through the MAS receptor expressed in the bronchial epithelium. Furthermore, these actions were attributed to the inhibition of the JNK signaling pathway (Hong et al., 2021).

In a fibrotic context, although little is known to date, AVE has had favorable implications in the resolution of different pathologies that develop this alteration. In a model of cardiac dysfunction in rats, induced by isoproterenol, the intraperitoneal administration of AVE attenuated the deposition of collagen in the left ventricle, in addition to reducing the presence of collagen type I, collagen III and fibronectin in the heart (Ferreira P. M. et al., 2007). In rats with myocardial infarction, AVE also attenuated the expression of collagen I and III, in addition to inhibiting the expression of TGF-β and TNF-α (Zeng et al., 2012). In a model of renal hypertension in rats, intragastric administration of AVE for 28 days was shown to be capable of reducing collagen deposition in renal tissue (Cunha et al., 2013; Cao et al., 2019). Cao et al. (2019), in a model of pulmonary fibrosis caused by LPS-induced ARDS, evaluated the effects of AVE, where they demonstrated that the application of this compound as an intraperitoneal treatment for 20 days was capable of attenuating lung injury by reducing the presence of collagen I fibers, the levels of TGF-β in bronchoalveolar fluid and plasma, the protein expression of E-cadherin and vimectin and the phosphorylation of Src kinase (Cao et al., 2019).